Gautam Ganguly, MD
Neurology · Whittier, CANPI 1215912522
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,630 of the $10,257 with a category attached, or 84.1%. It is spread thinly across 47 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,974 and has fallen 61.6% since, to $1,525 in 2025.
Across 375 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$2K
- UCB, Inc.$1K
- AbbVie$1K
- Novartis$1K
- Lilly USA, LLC$319
- Biogen$316
- plus $4K from 41 others
What the payments were for
- Consulting fees$1,43814%
- Food & beverage$8,63084%
- Education$1902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$1,438
- VNS Therapy$240
- Rystiggo$123
- GOCOVRI$121
How this compares
$10,257 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 13 | $163,672 |
| GilenyaFingolimod Hcl | 13 | $135,240 |
| AubagioTeriflunomide | 11 | $99,194 |
| AmpyraDalfampridine | 13 | $54,233 |
| RytaryCarbidopa/Levodopa | 22 | $35,764 |
| Nurtec OdtRimegepant Sulfate | 17 | $32,863 |
| VimpatLacosamide | 13 | $17,836 |
| RexultiBrexpiprazole | 12 | $15,578 |
| BotoxOnabotulinumtoxina | 13 | $11,066 |
| Levetiracetam | 201 | $9,123 |
| Memantine Hcl | 187 | $7,051 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 151 | $6,341 |
| Lacosamide | 43 | $5,984 |
| Rasagiline Mesylate | 22 | $4,402 |
| Gabapentin | 202 | $4,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $293 | $163,67213 claims |
| NovartisGilenya | $1,072 | $135,24013 claims |
| SanofiAubagio | $55 | $99,19411 claims |
| Acorda Therapeutics, IncAmpyra | $108 | $54,23313 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $79 | $37,36038 claims |
| PfizerNurtec Odt | $188 | $32,86317 claims |
| UCB, Inc.Vimpat | $1,284 | $17,83613 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $74 | $15,57812 claims |
| AbbVieBotox | $1,191 | $11,06613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.
Other neurology in Whittier
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.